SNPX - Synaptogenix, Inc. Stock Price, Fair Value and News

$3.27-0.33 (-9.17%)

Delayed as of 23 Oct 2024, 02:33 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SNPX Price Action

Last 7 days

9.5%

Last 90 days

-27.8%

Trailing 12 Months

-58.3%

SNPX RSI Chart

SNPX Valuation

Market Cap

4.7M

Price/Earnings (Trailing)

-2.76

Price/Sales (Trailing)

2.92

EV/EBITDA

11.86

Price/Free Cashflow

-0.96

SNPX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SNPX Fundamentals

SNPX Revenue

Revenue (TTM)

1.6M

Rev. Growth (Yr)

-22.63%

Rev. Growth (Qtr)

-28.68%

SNPX Earnings

Earnings (TTM)

-1.7M

Earnings Growth (Yr)

68.9%

Earnings Growth (Qtr)

-516.02%

SNPX Profitability

EBT Margin

-105.77%

Return on Equity

-9.11%

Return on Assets

-6.03%

Free Cashflow Yield

-104.05%

SNPX Investor Care

Shares Dilution (1Y)

223.26%

Diluted EPS (TTM)

-27.36

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	1.6M	0	0
2023	726.8K	1.1M	1.5M	1.6M
2022	30.6K	54.1K	192.3K	335.0K
2021	0	104.5K	55.8K	7.1K
2020	322.3K	266.0K	209.6K	153.2K
2019	0	0	0	378.7K

Get all data in R, Python etc through our Historical Stock Data APIs

About Synaptogenix, Inc.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

CEO	Dr. Alan J. Tuchman M.D., MBA(FAAN)
WEBSITE	synaptogen.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	5

Synaptogenix, Inc. Frequently Asked Questions

What is the ticker symbol for Synaptogenix, Inc.? What does SNPX stand for in stocks?

SNPX is the stock ticker symbol of Synaptogenix, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Synaptogenix, Inc. (SNPX)?

As of Mon Oct 21 2024, market cap of Synaptogenix, Inc. is 4.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNPX stock?

You can check SNPX's fair value in chart for subscribers.

Is Synaptogenix, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNPX is over valued or under valued. Whether Synaptogenix, Inc. is cheap or expensive depends on the assumptions which impact Synaptogenix, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNPX.

What is Synaptogenix, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 21 2024, SNPX's PE ratio (Price to Earnings) is -2.76 and Price to Sales (PS) ratio is 2.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNPX PE ratio will change depending on the future growth rate expectations of investors.